Table 1 Novel CAR T-cell agents for relapsed/refractory B-cell malignancies
Product | Phase | Target | Reconstruction method | Indication | T cells | Clinical trial identifier | References |
|---|---|---|---|---|---|---|---|
ssCART−19 | I/II | CD19 | shRNA-IL−6 gene silencing element | R/R B-ALL | Autologous | NCT03919240 | [5] |
WZTL−002 | I | CD19 | CD28 and TLR2 co-stimulatory domains | R/R B-NHL | Autologous | NCT04049513 | [6] |
19(T2)28z1XX | I | CD19 | Mutating 2 of the 3 ITAMs | R/R DLBCL | Autologous | NCT04464200 | [7] |
BRL−201 | I | CD19 | Non-viral PD−1 locus specific integration via CRISPR-Cas9 | R/R B-NHL | Autologous | NCT04213469 | [8] |
UCART20×22 | I/IIa | CD20/CD22 | N/A | R/R B-NHL | Donor | NCT05607420 | [9] |
CD19/CD70 CAR T-cells | I/II | CD19/CD70 | N/A | R/R DLBCL | Autologous | NCT03125577 | [10] |
C-CAR039 | I | CD20/CD19 | N/A | R/R B-NHL | Autologous | NCT04693676/NCT04696432/NCT04655677/NCT04317885 | [11] |
ONCT−808 | I/II | ROR1 | N/A | R/R BCL | Autologous | NCT05588440 | [12] |